Abridge vs Niramai

Abridge has a disclosed valuation of $850M, while Niramai's valuation is not publicly available, making a direct size comparison difficult. Abridge employs 120 people.

Abridge has raised more in total funding at $150M, compared to Niramai's $17M — a gap of $133M. Combined, the two companies have completed 6 known funding rounds.

Abridge holds the higher Awaira Score at 76/100, compared to Niramai's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 16-point gap that reflects meaningful differences in scale or traction.

Abridge was founded by Shiv Rao in 2018. Niramai was founded by Geetha Manjunath in 2016. Visit each company's profile on Awaira for a full founder biography.

Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology leverages natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence. Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare innovation and a major Indian public health challenge.

Niramai was founded first in 2016, giving it 2 years of additional market experience. Abridge was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Abridge has approximately 120 employees, while Niramai has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Abridge and Niramai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.